NASDAQ:APTX - Aptinyx Stock Price, Forecast & News

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx Inc (NASDAQ:APTX) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.44) EPS for the quarter, hitting analysts' consensus estimates of ($0.44). The company earned $0.94 million during the quarter, compared to analysts' expectations of $0.91 million. Aptinyx had a negative return on equity of 44.24% and a negative net margin of 1,523.09%. View Aptinyx's Earnings History.

Aptinyx is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Aptinyx.

6 brokerages have issued 1-year price objectives for Aptinyx's shares. Their forecasts range from $7.00 to $12.00. On average, they anticipate Aptinyx's stock price to reach $10.33 in the next year. This suggests a possible upside of 220.9% from the stock's current price. View Analyst Price Targets for Aptinyx.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.

News coverage about APTX stock has been trending extremely negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aptinyx earned a daily sentiment score of -4.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Aptinyx.

Aptinyx saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 192,200 shares, an increase of 13.4% from the January 15th total of 169,500 shares. Based on an average trading volume of 240,200 shares, the short-interest ratio is currently 0.8 days. Currently, 0.9% of the company's stock are short sold. View Aptinyx's Current Options Chain.

Some companies that are related to Aptinyx include Omeros (OMER), Molecular Templates (MTEM), Emisphere Technologies (EMIS), Kura Oncology (KURA), RAPT Therapeutics (RAPT), XBiotech (XBIT), Crinetics Pharmaceuticals (CRNX), AC Immune (ACIU), Neoleukin Therapeutics (NLTX), Milestone Pharmaceuticals (MIST), Morphic (MORF), Assembly Biosciences (ASMB), Sinovac Biotech (SVA), TherapeuticsMD (TXMD) and CytoDyn (CYDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), ADMA Biologics (ADMA), Canopy Growth (CGC), Kadmon (KDMN), Inovio Pharmaceuticals (INO), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Aptinyx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Farallon Capital Management LLC (0.93%), Renaissance Technologies LLC (0.70%), Jacobs Levy Equity Management Inc. (0.43%), Oxford Asset Management LLP (0.40%), Marshall Wace LLP (0.33%) and Acadian Asset Management LLC (0.26%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Institutional Ownership Trends for Aptinyx.

APTX stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Marshall Wace LLP, Oxford Asset Management LLP, Russell Investments Group Ltd., Alambic Investment Management L.P. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Aptinyx.

APTX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., DCF Advisers LLC, Spark Investment Management LLC and Acadian Asset Management LLC. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Insider Buying and Selling for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $3.22.

Aptinyx has a market capitalization of $141.18 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. View Additional Information About Aptinyx.

The official website for Aptinyx is http://www.aptinyx.com/.

Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]